USP1-WDR48 deubiquitinase complex enhances TGF-β induced epithelial–mesenchymal transition of TNBC cells via stabilizing TAK1

References

• Denkert C, Liedtke C, Tutt A, et al. Molecular alterations in triple-negative breast cancer-the road to new treatment strategies. Lancet. 2017;389(10087):2430–2442.
   PubMed Web of Science ®Google Scholar
• Hammond ME, Hayes DF, Dowsett M, et al. American society of clinical oncology/college of american pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 2010;28(16):2784–2795.
   PubMed Web of Science ®Google Scholar
• Wolff AC, Hammond MEH, Allison KH, et al. Human epidermal growth factor receptor 2 testing in breast cancer: American society of clinical oncology/college of american pathologists clinical practice guideline focused update. J Clin Oncol. 2018;36(20):2105–2122.
   PubMed Web of Science ®Google Scholar
• Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med. 2010;363(20):1938–1948.
   PubMed Web of Science ®Google Scholar
• Zeichner SB, Terawaki H, Gogineni K. A review of systemic treatment in metastatic triple-negative breast cancer. Breast Cancer: Basic and Clinical Research. 2016;10:25–36.
   PubMed Web of Science ®Google Scholar
• Xu X, Zhang L, He X, et al. TGF-beta plays a vital role in triple-negative breast cancer (TNBC) drug-resistance through regulating stemness, EMT and apoptosis. Biochem Biophys Res Commun. 2018;502(1):160–165.
   PubMed Web of Science ®Google Scholar
• Bhola NE, Balko JM, Dugger TC, et al. TGF-beta inhibition enhances chemotherapy action against triple-negative breast cancer. J Clin Invest. 2013;123(3):1348–1358.
   PubMed Web of Science ®Google Scholar
• Derynck R, Akhurst RJ, Balmain A. TGF-beta signaling in tumor suppression and cancer progression. Nat Genet. 2001;29:117–129.
   PubMed Web of Science ®Google Scholar
• Dumont N, Arteaga CL. Targeting the TGF beta signaling network in human neoplasia. Cancer Cell. 2003;3(6):531–536.
   PubMed Web of Science ®Google Scholar
• Massague J. TGF-beta signal transduction. Annu Rev Biochem. 1998;67(1):753–791.
   PubMedGoogle Scholar
• Maris P, Blomme A, Palacios AP, et al. Asporin is a fibroblast-derived TGF-beta1 inhibitor and a tumor suppressor associated with good prognosis in breast cancer. PLoS Med. 2015;12(9):e1001871.
   PubMed Web of Science ®Google Scholar
• Derynck R, Budi EH. Specificity, versatility, and control of TGF-beta family signaling. Sci Signal. 2019;12(570):eaav5183.
   Web of Science ®Google Scholar
• Sorrentino A, Thakur N, Grimsby S, et al. The type I TGF-beta receptor engages TRAF6 to activate TAK1 in a receptor kinase-independent manner. Nat Cell Biol. 2008;10(10):1199–1207.
   PubMed Web of Science ®Google Scholar
• Yamaguchi K, Shirakabe K, Shibuya H, et al. Identification of a member of the MAPKKK family as a potential mediator of TGF-beta signal transduction. Science. 1995;270(5244):2008–2011.
   PubMed Web of Science ®Google Scholar
• Skaug B, Jiang X, Chen ZJ. The role of ubiquitin in NF-kappaB regulatory pathways. Annu Rev Biochem. 2009;78(1):769–796.
   PubMedGoogle Scholar
• Sakurai H. Targeting of TAK1 in inflammatory disorders and cancer. Trends Pharmacol Sci. 2012;33(10):522–530.
   PubMed Web of Science ®Google Scholar
• Yumoto K, Thomas PS, Lane J, et al. TGF-β-activated kinase 1 (Tak1) mediates agonist-induced Smad activation and linker region phosphorylation in embryonic craniofacial neural crest-derived cells. J Biol Chem. 2013;288(19):13467–13480.
   PubMed Web of Science ®Google Scholar
• Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. 2014;15:178–196.
   PubMed Web of Science ®Google Scholar
• Zavadil J, Bitzer M, Liang D, et al. Genetic programs of epithelial cell plasticity directed by transforming growth factor-beta. Proc Natl Acad Sci U S A. 2001;98(12):6686–6691.
   PubMed Web of Science ®Google Scholar
• Landström M. The TAK1-TRAF6 signalling pathway. Int J Biochem Cell Biol. 2010;42(5):585–589.
   PubMed Web of Science ®Google Scholar
• Davies M, Robinson M, Smith E, et al. Induction of an epithelial to mesenchymal transition in human immortal and malignant keratinocytes by TGF-beta1 involves MAPK, Smad and AP-1 signalling pathways. J Cell Biochem. 2005;95(5):918–931.
   PubMed Web of Science ®Google Scholar
• Peinado H, Quintanilla M, Cano A. Transforming growth factor beta-1 induces snail transcription factor in epithelial cell lines: mechanisms for epithelial mesenchymal transitions. J Biol Chem. 2003;278(23):21113–21123.
   PubMed Web of Science ®Google Scholar
• Tripathi V, Shin JH, Stuelten CH, et al. TGF-β-induced alternative splicing of TAK1 promotes EMT and drug resistance. Oncogene. 2019;38(17):3185–3200.
   PubMed Web of Science ®Google Scholar
• Dong N, Tang X, Yuan XY, et al. [TAK1 promotes epithelial-mesenchymal transition of lens epithelial cells]. Zhonghua Yan Ke Za Zhi. 2016;52:278–284.
   PubMedGoogle Scholar
• Suriyamurthy S, Baker D, Ten Dijke P, et al. Epigenetic reprogramming of TGF-β signaling in breast cancer. Cancers (Basel). 2008;10(5):726.
   Google Scholar
• Pang MF, Georgoudaki AM, Lambut L, et al. TGF-beta1-induced EMT promotes targeted migration of breast cancer cells through the lymphatic system by the activation of CCR7/CCL21-mediated chemotaxis. Oncogene. 2016;35(6):748–760.
   PubMed Web of Science ®Google Scholar
• Han G. Distinct mechanisms of TGF- 1-mediated epithelial-to-mesenchymal transition and metastasis during skin carcinogenesis. J Clin Invest. 2012;33(7):1714–1723.
   Google Scholar
• Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest. 2010;42(6):1420–1428.
   Google Scholar
• Korpal M, Yan J, Lu X, et al. Imaging transforming growth factor-β signaling dynamics and therapeutic response in breast cancer bone metastasis. Nat Med. 2003;278(8):960–966.
   Google Scholar
• Kim S, Lee J, Jeon M, et al. Elevated TGF-beta1 and -beta2 expression accelerates the epithelial to mesenchymal transition in triple-negative breast cancer cells. Cytokine. 2015;75(1):151–158.
   PubMed Web of Science ®Google Scholar
• Kim S, Lee J, You D, et al. Berberine suppresses cell motility through downregulation of TGF-β1 in triple negative breast cancer cells. Cellular Physiology and Biochemistry. 2019;38(2):795–807.
   Google Scholar
• Yamashita M, Fatyol K, Jin C, et al. TRAF6 mediates Smad-independent activation of JNK and p38 by TGF-beta. Mol Cell. 2008;31(6):918–924.
   PubMed Web of Science ®Google Scholar
• Zhang L, Zhou F, García de Vinuesa A, et al. TRAF4 promotes TGF-β receptor signaling and drives breast cancer metastasis. Mol Cell. 2013;51(5):559–572.
   PubMed Web of Science ®Google Scholar
• Wu X, Zhang W, Font-Burgada J, et al. Ubiquitin-conjugating enzyme Ubc13 controls breast cancer metastasis through a TAK1-p38 MAP kinase cascade. Proc Natl Acad Sci U S A. 2014;111(38):13870–13875.
   PubMed Web of Science ®Google Scholar
• Pal A, Huang W, Li X, et al. CCN6 modulates BMP signaling via the Smad-independent TAK1/p38 pathway, acting to suppress metastasis of breast cancer. Cancer Res. 2012;72(18):4818–4828.
   PubMed Web of Science ®Google Scholar
• Jiang L, Yu L, Zhang X, et al. miR-892b silencing activates NF-κB and promotes aggressiveness in breast cancer. Cancer Res. 2009;119(5):1101–1111.
   Google Scholar
• Wang Z, Zhang H, Shi M, et al. TAK1 inhibitor NG25 enhances doxorubicin-mediated apoptosis in breast cancer cells. Sci Rep. 2016;6(1):32737.
   PubMedGoogle Scholar
• Iriondo O, Liu Y, Lee G, et al. TAK1 mediates microenvironment-triggered autocrine signals and promotes triple-negative breast cancer lung metastasis. Nat Commun. 2018;9(1):1994.
   PubMedGoogle Scholar
• Nolte M, Margadant C. Controlling Immunity and Inflammation through integrin-dependent regulation of TGF-beta. Trends Cell Biol. 2020;30(1):49–59.
   PubMed Web of Science ®Google Scholar
• Zhang L, Zhou F, Drabsch Y, et al. USP4 is regulated by AKT phosphorylation and directly deubiquitylates TGF-beta type I receptor. Nat Cell Biol. 2012;14(7):717–726.
   PubMed Web of Science ®Google Scholar
• Ying X, Zhao Y, Yao T, et al. Novel protective role for ubiquitin-specific protease 18 in pathological cardiac remodeling. Hypertension. 2016;68(5):1160–1170.
   PubMed Web of Science ®Google Scholar
• Galant C, Marchandise J, Stoenoiu MS, et al. Overexpression of ubiquitin-specific peptidase 15 in systemic sclerosis fibroblasts increases response to transforming growth factor beta. Rheumatology (Oxford). 2019;58(4):708–718.
   PubMed Web of Science ®Google Scholar
• Cohn MA, Kee Y, Haas W, et al. UAF1 is a subunit of multiple deubiquitinating enzyme complexes. J Biol Chem. 2009;284(8):5343–5351.
   PubMed Web of Science ®Google Scholar
• Sowa ME, Bennett EJ, Gygi SP, et al. Defining the human deubiquitinating enzyme interaction landscape. Cell. 2009;138(2):389–403.
   PubMed Web of Science ®Google Scholar
• Yu Z, Song H, Jia M, et al. USP1-UAF1 deubiquitinase complex stabilizes TBK1 and enhances antiviral responses. J Exp Med. 2017;214(12):3553–3563.
   PubMed Web of Science ®Google Scholar
• Sonego M, Pellarin I, Costa A, et al. USP1 links platinum resistance to cancer cell dissemination by regulating snail stability. Sci Adv. 2019;5(5):eaav3235.
   PubMed Web of Science ®Google Scholar
• Ma A, Tang M, Zhang L, et al. USP1 inhibition destabilizes KPNA2 and suppresses breast cancer metastasis. Oncogene. 2019;38(13):2405–2419.
   PubMed Web of Science ®Google Scholar